"We are pleased to have two applications for nivolumab now under review in the E.U., and look forward to continued collaboration with health authorities around the world as we work to bring nivolumab to patients." "Lung cancer is the leading cause of cancer death worldwide, and there remains a significant need for effective treatment options for patients with this disease," said Michael Giordano, M.D., senior vice president, Head of Oncology Development, Bristol-Myers Squibb.
http://ift.tt/YFOm0i
http://ift.tt/YFOm0i
No comments:
Post a Comment